Valion Bio Inc (VBIO)

$0.56 -0.02 (-3.88%)
Market Cap 1.78M
Revenue (ttm) 0.00
Net Income (ttm) -8.88M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.27
Volume 93,400
Avg Vol 377,610
Day's Range N/A - N/A
Shares Out 3.20M
Stochastic %K 63%
Beta 1.79
Analysts Strong Buy
Price Target $3.50

Company Profile

Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, In...

Industry: Biotechnology
Sector: Healthcare
Phone: 888 276 6888
Address:
1305 E. Houston Street, Suite 311, Building 1, San Antonio, United States
jpurr
jpurr Jun. 26 at 2:46 PM
$VBIO Shorts like beatwallstreet are blowing hot air
0 · Reply
BEATWALLSTREET
BEATWALLSTREET Jun. 26 at 1:56 AM
$VBIO $TIVC $STAB Milton Todd ault aka jabba The hutt of the stock market. Now you know like I said all you have to do is follow these scammers and short everything they touch!
3 · Reply
BEATWALLSTREET
BEATWALLSTREET Jun. 26 at 12:52 AM
$VBIO if they truly believed this was a sure thing, insiders would be loading up hand over fist not dumping every share they can with the company sitting at a $1.5 million market cap. Actions speak louder than press releases.
2 · Reply
BEATWALLSTREET
BEATWALLSTREET Jun. 25 at 11:50 PM
$VBIO After dropping that fake news in the morning, they dumped more shares, but there wasn't enough volume because bagholders were a little more cautious after what happened last time. So the scammers switched tactics they covered some shorts and slowed the dilution, letting the stock recover. Bagholders thought, "This is it," and started buying again. Then boom... dilution and shorting resumed. Same trap, different day.
0 · Reply
urgetosurge
urgetosurge Jun. 25 at 8:08 PM
$VBIO inflection reversal day? Open, close, volume, all there. Obv lags, my key indicator. Time will tell.
0 · Reply
tardwrangler420
tardwrangler420 Jun. 25 at 7:19 PM
$VBIO called this yesterday!!
0 · Reply
carefour
carefour Jun. 25 at 7:16 PM
$VBIO send it
0 · Reply
carefour
carefour Jun. 25 at 7:16 PM
$VBIO in
0 · Reply
Dailyfollower
Dailyfollower Jun. 25 at 6:48 PM
$VBIO 💥
0 · Reply
tardwrangler420
tardwrangler420 Jun. 25 at 4:51 PM
$VBIO seeing some green on the day
0 · Reply
Latest News on VBIO
AFRRI/NIAID Designs Proprietary PBI-BM2.5 Protocol to Evaluate Valion Bio's (NASDAQ: VBIO) Entolimod as the First and Only Treatment for GI-ARS

Jun 25, 2026, 7:45 AM EDT - 4 days ago

AFRRI/NIAID Designs Proprietary PBI-BM2.5 Protocol to Evaluate Valion Bio's (NASDAQ: VBIO) Entolimod as the First and Only Treatment for GI-ARS

Valion Bio (NASDAQ: VBIO) Confirms U.S. House Armed Services Committee Initiative to Address Urgent Need for Radiation /Nuclear Countermeasures

Jun 11, 2026, 7:45 AM EDT - 18 days ago

Valion Bio (NASDAQ: VBIO) Confirms U.S. House Armed Services Committee Initiative to Address Urgent Need for Radiation /Nuclear Countermeasures

Valion Bio Transcript: AGM 2026

May 28, 2026, 1:00 PM EDT - 4 weeks ago

Valion Bio Transcript: AGM 2026

VALION BIO BRIEFS SENIOR DEPARTMENT OF WAR AND BARDA OFFICIALS IN JOINT ENGAGEMENT ON ENTOLIMOD FOR ACUTE RADIATION SYNDROME

May 19, 2026, 4:38 PM EDT - 5 weeks ago

VALION BIO BRIEFS SENIOR DEPARTMENT OF WAR AND BARDA OFFICIALS IN JOINT ENGAGEMENT ON ENTOLIMOD FOR ACUTE RADIATION SYNDROME

Valion Bio’s Velocity Bioworks licenses LarmorBio’s BioScan-NMR platform

2026-05-14T22:26:28.000Z - 6 weeks ago

Valion Bio’s Velocity Bioworks licenses LarmorBio’s BioScan-NMR platform

Valion Bio reports Q1 EPS ($2.23) vs. ($2.52) last year

2026-05-14T21:41:38.000Z - 6 weeks ago

Valion Bio reports Q1 EPS ($2.23) vs. ($2.52) last year

Valion Bio's Velocity Bioworks Secures Exclusive Commercial License to LarmorBio's BioScan-NMR™ Platform

May 14, 2026, 4:31 PM EDT - 6 weeks ago

Valion Bio's Velocity Bioworks Secures Exclusive Commercial License to LarmorBio's BioScan-NMR™ Platform

Valion Bio Earnings Call Transcript: Q1 2026

May 14, 2026, 4:30 PM EDT - 6 weeks ago

Valion Bio Earnings Call Transcript: Q1 2026

Valion Bio Earnings release: Q1 2026

May 14, 2026, 4:30 PM EDT - 6 weeks ago

Valion Bio Earnings release: Q1 2026

Valion Bio Quarterly report: Q1 2026

May 14, 2026, 4:30 PM EDT - 6 weeks ago

Valion Bio Quarterly report: Q1 2026

VALION BIO REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS

May 14, 2026, 4:05 PM EDT - 6 weeks ago

VALION BIO REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS

Valion Bio to Report First Quarter 2026 Financial Results on May 14, 2026

May 11, 2026, 8:01 AM EDT - 7 weeks ago

Valion Bio to Report First Quarter 2026 Financial Results on May 14, 2026

Valion Bio Celebrates Grand Opening of Velocity Bioworks Biomanufacturing Facility in San Antonio, Anchoring Domestic Production of Entolimod™

May 6, 2026, 8:08 AM EDT - 7 weeks ago

Valion Bio Celebrates Grand Opening of Velocity Bioworks Biomanufacturing Facility in San Antonio, Anchoring Domestic Production of Entolimod™

Valion Bio receives first study protocol under agreement with NIAID

2026-05-05T12:15:18.000Z - 7 weeks ago

Valion Bio receives first study protocol under agreement with NIAID

VALION BIO RECEIVES FIRST FDA-PRECEDENT STUDY PROTOCOL FROM NIAID FOR ENTOLIMOD™; FEDERAL AGENCY TO FULLY FUND BLA-ENABLING IN VIVO PROGRAM AND CO-NAVIGATE FDA SUBMISSION

May 5, 2026, 8:00 AM EDT - 7 weeks ago

VALION BIO RECEIVES FIRST FDA-PRECEDENT STUDY PROTOCOL FROM NIAID FOR ENTOLIMOD™; FEDERAL AGENCY TO FULLY FUND BLA-ENABLING IN VIVO PROGRAM AND CO-NAVIGATE FDA SUBMISSION

Valion Bio names Melinda Lackey as General Counsel

2026-05-04T20:42:49.000Z - 7 weeks ago

Valion Bio names Melinda Lackey as General Counsel

TCRT

Valion Bio Appoints Melinda Lackey as General Counsel

May 4, 2026, 4:05 PM EDT - 7 weeks ago

Valion Bio Appoints Melinda Lackey as General Counsel

TCRT

Valion Bio Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 2 months ago

Valion Bio Proxy statement: Proxy filing

VALION BIO BRIEFS PENTAGON LEADERSHIP ON ENTOLIMOD™ FOR ACUTE RADIATION SYNDROME

Apr 28, 2026, 8:01 AM EDT - 2 months ago

VALION BIO BRIEFS PENTAGON LEADERSHIP ON ENTOLIMOD™ FOR ACUTE RADIATION SYNDROME

Tivic Health Systems Rebrands as Valion Bio, Reflecting Completed Transformation into a Late-Stage Biopharmaceutical Company with Government-Backed Asset and Potential Multiple Revenue Stream Model

Apr 23, 2026, 4:05 PM EDT - 2 months ago

Tivic Health Systems Rebrands as Valion Bio, Reflecting Completed Transformation into a Late-Stage Biopharmaceutical Company with Government-Backed Asset and Potential Multiple Revenue Stream Model

Valion Bio Proxy statement: Proxy filing

Apr 20, 2026, 8:00 AM EDT - 2 months ago

Valion Bio Proxy statement: Proxy filing

Tivic Health Selected to Present Entolimod™ as a Radiation Countermeasure and its Plans for an Oral Transmucosal Program to the Department of War Tech Watch Program on May 7th

Apr 15, 2026, 8:00 AM EDT - 2 months ago

Tivic Health Selected to Present Entolimod™ as a Radiation Countermeasure and its Plans for an Oral Transmucosal Program to the Department of War Tech Watch Program on May 7th

Valion Bio Registration statement: Registration filing

Apr 13, 2026, 8:00 AM EDT - 2 months ago

Valion Bio Registration statement: Registration filing

Valion Bio Transcript: Emerging Growth Conference 91

Apr 1, 2026, 2:55 PM EDT - 3 months ago

Valion Bio Transcript: Emerging Growth Conference 91

Tivic Receives Formal Request for Information from Ukrainian Ministry of Health Regarding Strategic Stockpiling of Entolimod

Mar 31, 2026, 8:30 AM EDT - 3 months ago

Tivic Receives Formal Request for Information from Ukrainian Ministry of Health Regarding Strategic Stockpiling of Entolimod

Tivic CEO To Present at the Upcoming Emerging Growth's April 2026 Virtual Conference

Mar 27, 2026, 11:30 AM EDT - 3 months ago

Tivic CEO To Present at the Upcoming Emerging Growth's April 2026 Virtual Conference

Tivic Secures NIAID Non-Clinical Evaluation Agreement for Entolimod, Targeting Gastrointestinal Acute Radiation Syndrome

Mar 26, 2026, 8:30 AM EDT - 3 months ago

Tivic Secures NIAID Non-Clinical Evaluation Agreement for Entolimod, Targeting Gastrointestinal Acute Radiation Syndrome

Valion Bio Earnings Call Transcript: Q4 2025

Mar 25, 2026, 4:30 PM EDT - 3 months ago

Valion Bio Earnings Call Transcript: Q4 2025

Valion Bio Annual report: Q4 2025

Mar 25, 2026, 4:30 PM EDT - 3 months ago

Valion Bio Annual report: Q4 2025

Valion Bio Earnings release: Q4 2025

Mar 25, 2026, 4:30 PM EDT - 3 months ago

Valion Bio Earnings release: Q4 2025

Tivic Reports Full Year 2025 Results

Mar 25, 2026, 4:05 PM EDT - 3 months ago

Tivic Reports Full Year 2025 Results

Tivic Health CEO Letter to Shareholders

Mar 24, 2026, 9:30 AM EDT - 3 months ago

Tivic Health CEO Letter to Shareholders

Tivic To Report 2025 Year-End Financial Results Via Conference Call and Webcast on March 25th at 1:30pm PT / 4:30pm ET

Mar 20, 2026, 3:35 PM EDT - 3 months ago

Tivic To Report 2025 Year-End Financial Results Via Conference Call and Webcast on March 25th at 1:30pm PT / 4:30pm ET

Valion Bio Transcript: EGM 2026

Mar 12, 2026, 4:00 PM EDT - 3 months ago

Valion Bio Transcript: EGM 2026

Biotech Veteran Michael K. Handley Named CEO of Tivic Health Systems to Spearhead Strategic Expansion in Biopharma

Mar 4, 2026, 8:30 AM EST - 4 months ago

Biotech Veteran Michael K. Handley Named CEO of Tivic Health Systems to Spearhead Strategic Expansion in Biopharma

Valion Bio Slides: Investor presentation

Mar 4, 2026, 6:00 AM EST - 4 months ago

Valion Bio Slides: Investor presentation

Tivic and BARDA Continue Discussions of Entolimod for Acute Radiation Syndrome on March 10

Feb 18, 2026, 9:15 AM EST - 4 months ago

Tivic and BARDA Continue Discussions of Entolimod for Acute Radiation Syndrome on March 10

Valion Bio Proxy statement: Proxy Filing

Feb 9, 2026, 7:00 AM EST - 5 months ago

Valion Bio Proxy statement: Proxy Filing

Tivic, BARDA Discuss Entolimod(TM) for Acute Radiation Syndrome at TechWatch Meeting

Jan 28, 2026, 8:30 AM EST - 5 months ago

Tivic, BARDA Discuss Entolimod(TM) for Acute Radiation Syndrome at TechWatch Meeting

Tivic to Showcase Strategic Pivot and Forward Outlook on Advancing Entolimod(TM) to Commercialization at DealFlow Discovery Conference

Jan 26, 2026, 10:10 AM EST - 5 months ago

Tivic to Showcase Strategic Pivot and Forward Outlook on Advancing Entolimod(TM) to Commercialization at DealFlow Discovery Conference

Valion Bio Transcript: Emerging Growth Conference 89

Jan 22, 2026, 4:10 PM EST - 5 months ago

Valion Bio Transcript: Emerging Growth Conference 89

Tivic CEO To Present at the Upcoming Emerging Growth's January 2026 Virtual Conference

Jan 20, 2026, 5:50 PM EST - 5 months ago

Tivic CEO To Present at the Upcoming Emerging Growth's January 2026 Virtual Conference

Valion Bio Slides: Investor presentation

Jan 20, 2026, 7:00 AM EST - 5 months ago

Valion Bio Slides: Investor presentation

Valion Bio Transcript: Investor Update

Jan 12, 2026, 4:30 PM EST - 5 months ago

Valion Bio Transcript: Investor Update

Tivic Delivers 200x Scale-up in Manufacturing for Lead Drug Candidate Entolimod(TM) And Achieves Reproducible Yields, Potency and Purity

Jan 12, 2026, 9:00 AM EST - 5 months ago

Tivic Delivers 200x Scale-up in Manufacturing for Lead Drug Candidate Entolimod(TM) And Achieves Reproducible Yields, Potency and Purity

Valion Bio Proxy statement: Proxy Filing

Jan 9, 2026, 7:00 AM EST - 6 months ago

Valion Bio Proxy statement: Proxy Filing

Tivic Announces Special Webcast To Discuss Its Recent Acquisition of CDMO Assets - Highlighting Near-Term Strategic Potential and Immediate Contributions to Accelerated Drug Development Timelines

Jan 8, 2026, 8:30 AM EST - 6 months ago

Tivic Announces Special Webcast To Discuss Its Recent Acquisition of CDMO Assets - Highlighting Near-Term Strategic Potential and Immediate Contributions to Accelerated Drug Development Timelines

Valion Bio Registration statement: Registration Filing

Dec 29, 2025, 7:00 AM EST - 6 months ago

Valion Bio Registration statement: Registration Filing

Valion Bio Registration statement: Registration Filing

Dec 29, 2025, 7:00 AM EST - 6 months ago

Valion Bio Registration statement: Registration Filing

Valion Bio Proxy statement: Proxy Filing

Dec 29, 2025, 7:00 AM EST - 6 months ago

Valion Bio Proxy statement: Proxy Filing

Tivic Acquires Ready-to-Scale cGMP Manufacturing and Development Assets to Accelerate Commercialization of Entolimod; Tivic Growth Backed By $90M+ Financing Package

Dec 11, 2025, 9:45 AM EST - 7 months ago

Tivic Acquires Ready-to-Scale cGMP Manufacturing and Development Assets to Accelerate Commercialization of Entolimod; Tivic Growth Backed By $90M+ Financing Package

Tivic Secures Barda Meeting for Entolimod(TM) for Acute Radiation Syndrome

Nov 18, 2025, 8:30 AM EST - 7 months ago

Tivic Secures Barda Meeting for Entolimod(TM) for Acute Radiation Syndrome

Tivic Reports Third Quarter 2025 Financial Results

Nov 14, 2025, 4:30 PM EST - 8 months ago

Tivic Reports Third Quarter 2025 Financial Results

Valion Bio Earnings Call Transcript: Q3 2025

Nov 14, 2025, 4:30 PM EST - 8 months ago

Valion Bio Earnings Call Transcript: Q3 2025

Valion Bio Quarterly report: Q3 2025

Nov 14, 2025, 4:30 PM EST - 8 months ago

Valion Bio Quarterly report: Q3 2025

Valion Bio Earnings release: Q3 2025

Nov 14, 2025, 4:30 PM EST - 8 months ago

Valion Bio Earnings release: Q3 2025

Tivic Health Reports Findings of Clinical Optimization Trial of Non-Invasive Cervical Vagus Nerve Stimulation (ncVNS)

Nov 13, 2025, 8:30 AM EST - 8 months ago

Tivic Health Reports Findings of Clinical Optimization Trial of Non-Invasive Cervical Vagus Nerve Stimulation (ncVNS)

Tivic Expands Intellectual Property Portfolio

Nov 10, 2025, 9:00 AM EST - 8 months ago

Tivic Expands Intellectual Property Portfolio

Tivic Health to Report Third Quarter 2025 Financial Results on November 14th Via Conference Call and Webcast

Nov 6, 2025, 9:30 AM EST - 8 months ago

Tivic Health to Report Third Quarter 2025 Financial Results on November 14th Via Conference Call and Webcast

Tivic CEO, Jennifer Ernst, to Join Panel at 8th Annual Northwell Health Innovation Constellation Forum on Thursday, Oct. 23

Oct 22, 2025, 2:00 PM EDT - 8 months ago

Tivic CEO, Jennifer Ernst, to Join Panel at 8th Annual Northwell Health Innovation Constellation Forum on Thursday, Oct. 23

Valion Bio Registration statement: Registration Filing

Oct 17, 2025, 8:00 AM EDT - 9 months ago

Valion Bio Registration statement: Registration Filing

Valion Bio Transcript: Emerging Growth Conference 2025

Sep 25, 2025, 11:25 AM EDT - 9 months ago

Valion Bio Transcript: Emerging Growth Conference 2025

Tivic Health CEO Jennifer Ernst to Present at Emerging Growth's September Virtual Conference

Sep 22, 2025, 8:30 AM EDT - 10 months ago

Tivic Health CEO Jennifer Ernst to Present at Emerging Growth's September Virtual Conference

Tivic Completes Verification of Entolimod™ Cell Line: First Step in Establishing CGMP Manufacturing for BLA Filing

Sep 10, 2025, 8:30 AM EDT - 10 months ago

Tivic Completes Verification of Entolimod™ Cell Line: First Step in Establishing CGMP Manufacturing for BLA Filing

Valion Bio Registration statement: Registration Filing

Aug 29, 2025, 8:00 AM EDT - 10 months ago

Valion Bio Registration statement: Registration Filing

Tivic Receives Two Investigational New Drug Applications for Entolimod™ for the Treatment of Acute Radiation Syndrome (ARS) and Advanced Cancers

Aug 20, 2025, 8:30 AM EDT - 11 months ago

Tivic Receives Two Investigational New Drug Applications for Entolimod™ for the Treatment of Acute Radiation Syndrome (ARS) and Advanced Cancers

Tivic Health Advances Discussions on Use of Entolimod as a Radiation Countermeasure at Military Health System Research Symposium 2025

Aug 15, 2025, 8:30 AM EDT - 11 months ago

Tivic Health Advances Discussions on Use of Entolimod as a Radiation Countermeasure at Military Health System Research Symposium 2025

Valion Bio Earnings Call Transcript: Q2 2025

Aug 14, 2025, 4:30 PM EDT - 11 months ago

Valion Bio Earnings Call Transcript: Q2 2025

Valion Bio Quarterly report: Q2 2025

Aug 14, 2025, 4:30 PM EDT - 11 months ago

Valion Bio Quarterly report: Q2 2025

Valion Bio Earnings release: Q2 2025

Aug 14, 2025, 4:30 PM EDT - 11 months ago

Valion Bio Earnings release: Q2 2025

Tivic Reports Second Quarter 2025 Financial Results

Aug 14, 2025, 4:00 PM EDT - 11 months ago

Tivic Reports Second Quarter 2025 Financial Results

Valion Bio Registration statement: Registration Filing

Aug 8, 2025, 8:00 AM EDT - 11 months ago

Valion Bio Registration statement: Registration Filing

Valion Bio Registration statement: Registration Filing

Aug 8, 2025, 8:00 AM EDT - 11 months ago

Valion Bio Registration statement: Registration Filing

Tivic Health to Report Second Quarter 2025 Financial Results on August 14th Via Conference Call and Webcast

Aug 7, 2025, 8:30 AM EDT - 11 months ago

Tivic Health to Report Second Quarter 2025 Financial Results on August 14th Via Conference Call and Webcast

Valion Bio Registration statement: Registration Filing

Jul 25, 2025, 8:00 AM EDT - 1 year ago

Valion Bio Registration statement: Registration Filing

Tivic Shareholders Approve Key Proposals in Support of Strategic Transformation; Lisa Wolf Appointed Permanent CFO

Jul 8, 2025, 8:30 AM EDT - 1 year ago

Tivic Shareholders Approve Key Proposals in Support of Strategic Transformation; Lisa Wolf Appointed Permanent CFO

Tivic Health Completes Optimization Study for Its Non-Invasive Vagus Nerve Stimulation Device

Jun 25, 2025, 8:30 AM EDT - 1 year ago

Tivic Health Completes Optimization Study for Its Non-Invasive Vagus Nerve Stimulation Device

Tivic Health Announces 2025 Annual Meeting of Stockholders

Jun 24, 2025, 8:30 AM EDT - 1 year ago

Tivic Health Announces 2025 Annual Meeting of Stockholders

Valion Bio Transcript: Life Sciences Virtual Investor Forum

Jun 11, 2025, 1:30 PM EDT - 1 year ago

Valion Bio Transcript: Life Sciences Virtual Investor Forum

Valion Bio Registration statement: Registration Filing

Jun 6, 2025, 8:00 AM EDT - 1 year ago

Valion Bio Registration statement: Registration Filing

Valion Bio Proxy statement: Proxy Filing

Jun 2, 2025, 8:00 AM EDT - 1 year ago

Valion Bio Proxy statement: Proxy Filing

Valion Bio Proxy statement: Proxy Filing

May 23, 2025, 8:00 AM EDT - 1 year ago

Valion Bio Proxy statement: Proxy Filing

Valion Bio Transcript: Sidoti May Micro-Cap Virtual Conference

May 22, 2025, 1:00 PM EDT - 1 year ago

Valion Bio Transcript: Sidoti May Micro-Cap Virtual Conference

Valion Bio Earnings Call Transcript: Q1 2025

May 15, 2025, 4:30 PM EDT - 1 year ago

Valion Bio Earnings Call Transcript: Q1 2025

Valion Bio Quarterly report: Q1 2025

May 15, 2025, 4:30 PM EDT - 1 year ago

Valion Bio Quarterly report: Q1 2025

Valion Bio Earnings release: Q1 2025

May 15, 2025, 4:30 PM EDT - 1 year ago

Valion Bio Earnings release: Q1 2025

Tivic Reports First Quarter 2025 Financial Results and Provides Updates on Business Transformation

May 15, 2025, 4:05 PM EDT - 1 year ago

Tivic Reports First Quarter 2025 Financial Results and Provides Updates on Business Transformation

Tivic Health Enters GMP Manufacturing Validation Agreement with Scorpius BioManufacturing in Preparation for FDA Submission

May 14, 2025, 8:30 AM EDT - 1 year ago

Tivic Health Enters GMP Manufacturing Validation Agreement with Scorpius BioManufacturing in Preparation for FDA Submission

Tivic Expands VNS Intellectual Property Portfolio

May 13, 2025, 8:30 AM EDT - 1 year ago

Tivic Expands VNS Intellectual Property Portfolio

Tivic Health to Report First Quarter 2025 Financial Results on May 15th Via Conference Call and Webcast

May 9, 2025, 8:30 AM EDT - 1 year ago

Tivic Health to Report First Quarter 2025 Financial Results on May 15th Via Conference Call and Webcast

Valion Bio Registration statement: Registration Filing

May 9, 2025, 8:00 AM EDT - 1 year ago

Valion Bio Registration statement: Registration Filing

Tivic Health Reports White House Briefing and FDA Meetings Secured Positive Interest in Potential Military and Defense Applications of Its Product Candidates

Apr 22, 2025, 8:30 AM EDT - 1 year ago

Tivic Health Reports White House Briefing and FDA Meetings Secured Positive Interest in Potential Military and Defense Applications of Its Product Candidates

Tivic Health Extends its Worldwide License of TLR5 Agonist Entolimod to Include the Treatment of Neutropenia

Apr 15, 2025, 8:30 AM EDT - 1 year ago

Tivic Health Extends its Worldwide License of TLR5 Agonist Entolimod to Include the Treatment of Neutropenia

Tivic Health Systems, Inc. Regains Compliance with NASDAQ Minimum Bid Price Listing Rule

Apr 10, 2025, 8:30 AM EDT - 1 year ago

Tivic Health Systems, Inc. Regains Compliance with NASDAQ Minimum Bid Price Listing Rule

Valion Bio Earnings Call Transcript: Q4 2024

Mar 21, 2025, 4:30 PM EDT - 1 year ago

Valion Bio Earnings Call Transcript: Q4 2024

Valion Bio Annual report: Q4 2024

Mar 21, 2025, 4:30 PM EDT - 1 year ago

Valion Bio Annual report: Q4 2024

Valion Bio Earnings release: Q4 2024

Mar 21, 2025, 4:30 PM EDT - 1 year ago

Valion Bio Earnings release: Q4 2024

Tivic Reports Year End 2024 Financial Results and Provides Overview of Strategy for Transformation and Growth

Mar 21, 2025, 4:00 PM EDT - 1 year ago

Tivic Reports Year End 2024 Financial Results and Provides Overview of Strategy for Transformation and Growth

Tivic Health to Report 2024 Year-End Financial Results on March 21st Via Conference Call and Webcast

Mar 13, 2025, 4:59 PM EDT - 1 year ago

Tivic Health to Report 2024 Year-End Financial Results on March 21st Via Conference Call and Webcast

jpurr
jpurr Jun. 26 at 2:46 PM
$VBIO Shorts like beatwallstreet are blowing hot air
0 · Reply
BEATWALLSTREET
BEATWALLSTREET Jun. 26 at 1:56 AM
$VBIO $TIVC $STAB Milton Todd ault aka jabba The hutt of the stock market. Now you know like I said all you have to do is follow these scammers and short everything they touch!
3 · Reply
BEATWALLSTREET
BEATWALLSTREET Jun. 26 at 12:52 AM
$VBIO if they truly believed this was a sure thing, insiders would be loading up hand over fist not dumping every share they can with the company sitting at a $1.5 million market cap. Actions speak louder than press releases.
2 · Reply
BEATWALLSTREET
BEATWALLSTREET Jun. 25 at 11:50 PM
$VBIO After dropping that fake news in the morning, they dumped more shares, but there wasn't enough volume because bagholders were a little more cautious after what happened last time. So the scammers switched tactics they covered some shorts and slowed the dilution, letting the stock recover. Bagholders thought, "This is it," and started buying again. Then boom... dilution and shorting resumed. Same trap, different day.
0 · Reply
urgetosurge
urgetosurge Jun. 25 at 8:08 PM
$VBIO inflection reversal day? Open, close, volume, all there. Obv lags, my key indicator. Time will tell.
0 · Reply
tardwrangler420
tardwrangler420 Jun. 25 at 7:19 PM
$VBIO called this yesterday!!
0 · Reply
carefour
carefour Jun. 25 at 7:16 PM
$VBIO send it
0 · Reply
carefour
carefour Jun. 25 at 7:16 PM
$VBIO in
0 · Reply
Dailyfollower
Dailyfollower Jun. 25 at 6:48 PM
$VBIO 💥
0 · Reply
tardwrangler420
tardwrangler420 Jun. 25 at 4:51 PM
$VBIO seeing some green on the day
0 · Reply
FaresM9
FaresM9 Jun. 25 at 4:31 PM
$VBIO
0 · Reply
Insdr
Insdr Jun. 25 at 4:28 PM
$VBIO "Entolimod, a potential first and only treatment for gastrointestinal acute radiation syndrome (GI-ARS)". This is a big deal by itself - not just for the Armed Forces, but civilian programs such as nuclear energy, space exploration, geological and mining, and of course healthcare (radiology, oncology, and nuclear medicine) fields.
0 · Reply
urgetosurge
urgetosurge Jun. 25 at 3:04 PM
$VBIO disregard the paid pump promoters..
1 · Reply
BioTuesdays
BioTuesdays Jun. 25 at 2:33 PM
$VBIO has announced that the Armed Forces Radiobiology Research Institute (AFRRI), in partnership with the National Institute of Allergy and Infectious Diseases (NIAID), has completed design of the survival efficacy protocol that will be used to evaluate the company's lead candidate, Entolimod, a potential first and only treatment for gastrointestinal acute radiation syndrome (GI-ARS). https://biotuesdays.com/2026/06/25/afrri-niaid-designs-pbi-bm2-5-protocol-to-evaluate-valions-entolimod-for-gi-ars/
0 · Reply
tardwrangler420
tardwrangler420 Jun. 25 at 2:28 PM
$VBIO
0 · Reply
BEATWALLSTREET
BEATWALLSTREET Jun. 25 at 1:44 PM
$VBIO the more you buy the more they print the lower it goes.
0 · Reply
BEATWALLSTREET
BEATWALLSTREET Jun. 25 at 1:22 PM
$VBIO
0 · Reply
Nakuldesai
Nakuldesai Jun. 25 at 1:19 PM
$VBIO these assholes dilute at every news. Reason for it to go down with every news.
0 · Reply
urgetosurge
urgetosurge Jun. 25 at 1:05 PM
$VBIO don't buy it'll be going lower thanks to the convertible financing.
1 · Reply
sandman7473
sandman7473 Jun. 25 at 12:19 PM
$VBIO nice dilution
0 · Reply
Caseyd123
Caseyd123 Jun. 25 at 12:08 PM
$VBIO 💩
0 · Reply
urgetosurge
urgetosurge Jun. 25 at 12:05 PM
$VBIO a board and ceo so corrupt or stupid to approve a shite destructive financing agreement. This is a quagmire death spiral unless they renegotiate or get bought out. Stupid corrupted morons at the helm.. Avoid this dilution crap.
0 · Reply